Bristol Myers and 2seventy bio’s Abecma survival data raise questions ahead of FDA’s adcomm

SAN DIEGO — The FDA in November delayed its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy for earlier lines of multiple myeloma treatment.

Now, new data show why the FDA plans to gather an advisory committee to review overall survival data from the…
Click here to view original post

Advertisement — Advertise with Biotech Networks